ARTICLE | Deals
More pharma buy-in for Amphista’s non-E3 ligase degraders
Deals with BMS and Merck KGaA, and investment from Novartis and Lilly, highlight interest in broadly expressed, essential degradation machinery
May 6, 2022 9:46 PM UTC
A pair of pharma deals bring Amphista a combined $74 million in upfront payments and more signals of confidence in the University of Dundee spinout’s stealthy approach to protein degradation, which hinges on undisclosed ubiquitin-proteasome system regulators that are more broadly expressed and essential to cell survival than first-generation E3 ligases.
Amphista Therapeutics Ltd. announced Wednesday separate partnerships with Bristol Myers Squibb Co. (NYSE:BMY) and the Merck Healthcare unit of Merck KGaA (Xetra:MRK) to develop targeted protein therapeutics. ...